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AntidepressantStudies using animal models have shown that depression affects the stability of the microbiota, but the
actual structure and composition in patients with major depressive disorder (MDD) are not well under-
stood. Here, we analyzed fecal samples from 46 patients with depression (29 active-MDD and 17
responded-MDD) and 30 healthy controls (HCs). High-throughput pyrosequencing showed that, accord-
ing to the Shannon index, increased fecal bacterial a-diversity was found in the active-MDD (A-MDD) vs.
the HC group but not in the responded-MDD (R-MDD) vs. the HC group. Bacteroidetes, Proteobacteria,
and Actinobacteria strongly increased in level, whereas that of Firmicutes was signiﬁcantly reduced in
the A-MDD and R-MDD groups compared with the HC group. Despite profound interindividual variabil-
ity, levels of several predominant genera were signiﬁcantly different between the MDD and HC groups.
Most notably, the MDD groups had increased levels of Enterobacteriaceae and Alistipes but reduced levels
of Faecalibacterium. A negative correlation was observed between Faecalibacterium and the severity of
depressive symptoms. These ﬁndings enable a better understanding of changes in the fecal microbiota
composition in such patients, showing either a predominance of some potentially harmful bacterial
groups or a reduction in beneﬁcial bacterial genera. Further studies are warranted to elucidate the tem-
poral and causal relationships between gut microbiota and depression and to evaluate the suitability of
the microbiome as a biomarker.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction et al., 2007). Despite the fact that antidepressant medication isDepression is a common, life-disrupting and highly recurrent
illness and a leading source of disability worldwide (Moussaviwidely used to treat depressive symptoms, 30–40% of patients do
not respond to current drug strategies (Rush et al., 2006). Studies
on depression have focused mainly on the genetic, behavioral,
and neurological aspects of the disease, although the contributions
of environmental risk factors and immune dysregulation to the eti-
ology of depression have gained signiﬁcant attention.
Accumulating evidence from animal studies supports the
hypothesis that gut microbiota play an important role in central
nervous system function, namely through inﬂammation, and the
hypothalamic–pituitary–adrenal (HPA) axis, and by affecting neu-
rotransmission (Bangsgaard Bendtsen et al., 2012; Collins et al.,
2012; Cryan and Dinan, 2012; Dinan and Cryan, 2013; Dinan
et al., 2013; Wang and Kasper, 2014). Although the pathways link-
ing gut bacteria with the brain are incompletely understood, ‘‘leaky
gut’’, induced by stress, could play a role (Rook and Lowry, 2008;
Rook et al., 2014). Speciﬁcally, increased translocation of bacterial
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vation of the immune system and HPA axis (Maes et al., 2012,
2013). These effects can be reversed in mice by oral administration
of probiotics (Ait-Belgnaoui et al., 2012, 2014; Savignac et al.,
2014). In line with these ﬁndings, human studies have demon-
strated increased bacterial translocation in mood disorders such
as depression (Maes et al., 2008, 2012). Indeed, recent reports of
trials using probiotics in healthy subjects demonstrated improve-
ments in depression or anxiety outcome measures (Messaoudi
et al., 2011).
These results indicate that gut bacteria could possess
therapeutic potential for mental illnesses. Within the past year,
accumulating experimental data has strongly supported the view
that depression could also inﬂuence microbiota composition.
O’Mahony et al. (2009) reported that the fecal microbiome compo-
sition of adult rats subjected to maternal separation was signiﬁ-
cantly altered compared with that of non-separated controls.
Bangsgaard Bendtsen et al. (2012) demonstrated that the commu-
nity microbiota structure of mice exposed to a prolonged restraint
stressor differed signiﬁcantly from that of non-stressed controls.
Bailey et al. (2011) observed that social stressors signiﬁcantly
altered the relative abundance of bacteria, particularly when
microbiota were assessed immediately following stressor expo-
sure. Despite such animal studies indicating an association
between gut microbiota and depression, this relationship remains
poorly understood in humans. Therefore, detailed assessment of
the fecal microbiota of depression patients should be undertaken
before ﬁrm conclusions are drawn.
Here, we investigated whether gut microbiota are altered dur-
ing major depressive episodes or in response to antidepressant
treatment. We also identiﬁed microbiota signatures speciﬁc for
depression and their relationships with clinical patterns and phys-
iological measures using massively parallel barcoded 454 pyrose-
quencing on 76 fecal samples taken from 46 patients diagnosed
with depression and 30 matched healthy controls (HCs).2. Methods
2.1. Subject selection
This study protocol was approved by the Ethics Committee of
The Seventh People’s Hospital of Hangzhou (Zhejiang, China).
After receiving a written description of the aim of this study, all
participants gave written informed consent prior to enrollment.
The recruitment of participants and the process of sample collec-
tion are depicted in Fig. 1.
Forty-six patients (age, 18–40 years) were ultimately recruited
from the Seventh People’s Hospital of Hangzhou in Hangzhou,
Zhejiang, from May 2013 to December 2013 (Table 2). One experi-
enced psychiatrist performed the screening examinations. The
Mini-International Neuropsychiatric Interview was used as a sys-
tematic psychiatric screening tool to detect preexisting psychiatric
disorders (Sheehan et al., 1998). The Structured Clinical Interview
for the Diagnostic and Statistical Manual of Mental Disorders-
Fourth Edition was used to verify major depressive disorder (First
et al., 1996). Participants completed the Hamilton’s Depression
Scale (HAMDS), a 24-item clinician-administered measure of
depression, to assess the severity of depressive symptoms
(Hamilton, 1960). The HAMDS generates scores from 0 to 63;
scores P20 are indicative of clinically signiﬁcant depression.
Depressive symptoms were also assessed using the
Montgomery–Asberg Depression Rating Scale (MADRS), a clini-
cian-related depression scale and one of the most commonly used
symptom severity scales for depression. It consists of 10 items
scored from 0 to 6 (Montgomery and Asberg, 1979). HC subjects(n = 30) from the same cohort were screened using a semi-struc-
tured clinical interview to exclude those with psychiatric or phys-
ical illnesses.
All subjects were examined clinically before sampling and were
subsequently divided into three groups: active-MDD (A-MDD)
group (n = 29), responding-MDD (R-MDD) group (n = 17), and
HCs (n = 30). The A-MDD group was deﬁned as having an HAMDS
scoreP20. The patients in the R-MDD group were deﬁned as those
with a baseline HAMDS scores P20 upon admission to the hospi-
tal. Fecal and serum samples were collected at the time of their
HAMDS scores showed a 50% reduction after 4 weeks treatment.
The following exclusion criteria were established: hypertension;
cardiovascular disease; diabetes mellitus; obesity; liver cirrhosis;
fatty liver disease; irritable bowel syndrome; inﬂammatory bowel
disease; drug or alcohol abuse in the last year; use of antibiotics,
probiotics, prebiotics, or synbiotics in the month before collection
of the fecal sample; and known active bacterial, fungal, or viral
infections.2.2. Fecal sample collection and DNA extraction
Fecal samples were collected in a sterile plastic cup after the
participants completed the HAMDS and MADRS assessments and
were kept in an icebox. Samples for bacterial genomic DNA extrac-
tion were delivered to the laboratory within 15 min and stored at
80 C. Fecal microbial DNA was extracted from 200-mg feces
using the QIAamp DNA Stool Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions, with the
additional glass-bead beating steps on a Mini-beadbeater
(FastPrep; Thermo Electron Corp., Boston, MA, USA). DNA was
quantiﬁed using a NanoDrop ND-1000 spectrophotometer
(Thermo Electron); integrity and size were assessed by 1.0% agar-
ose gel electrophoresis on gels containing 0.5 mg/mL ethidium bro-
mide. DNA was stored at 20 C before analysis.2.3. Serum cytokine and BDNF detection
Blood samples were collected immediately after the HAMDS
and MADRS assessment, transferred to the laboratory immediately
in an icebox and stored at 80 C within 15 min after preparation
for further analysis. Serum tumor necrosis factor-a (TNF-a), inter-
leukin-1b (IL)-1b, IL-6, and brain-derived neurotrophic factor
(BDNF) levels were determined using commercially available
enzyme-linked immunosorbent assay kits (RayBiotech, Norcross,
GA, USA).2.4. Polymerase chain reaction (PCR) and pyrosequencing
Triplicate PCR reactions were performed on each sample. The
bacterial genomic DNA was ampliﬁed with the 27F (50-AGAGTTT
GATCCTGGCTCAG-30) and 533R (50-TTACCGCGGCTGCTGGCAC-30)
primers speciﬁc for the V1–V3 hypervariable regions of the 16S
rRNA gene. Each forward primer incorporated FLX Titanium adap-
ters and a sample barcode at the 50 end of the reverse primer to
allow all samples to be included in a single 454 FLX sequencing
run (Table S1). All PCRs were performed in 50-lL triplicates and
combined after PCR. The products were extracted with the
QIAquick Gel Extraction kit (Qiagen) and quantiﬁed on a
NanoDrop ND-1000 spectrophotometer, QuantiFluor-ST ﬂuorome-
ter (Promega, Madison, WI, USA), and an Agilent 2100 bioanalyzer
(Agilent Technologies, Palo Alto, CA, USA). Equimolar concentra-
tions of the 76 samples were pooled and sequenced on a 454
Life Sciences genome sequencer FLX system (Roche, Basel,
Switzerland) according to the manufacturer’s recommendations.
Fig. 1. The recruitment of participants and the process of sample collection.
Table 1
Comparison of phylotype coverage and diversity estimation of the 16S rRNA gene libraries at 97% similarity from the pyrosequencing analysis.
Group No. of reads No. of OTUsa Good’s (%)b Richness estimator Diversity index
ACE 95%CI Chao 1 95%CI Shannon Simpson Evennessc
HCs 229,038 8271 97.83 28,714 27,970–29,486 18,712 17,892–19,602 5.038359 0.023243 0.005202
A-MDD 244,508 10,365 97.55 31,911 31,173–32,675 21,584 20,796–22,431 5.344609* 0.019268 0.005007
R-MDD 135,029 6737 97.04 21,848 21,224–22,498 14,982 14,266–15,766 4.987910 0.027811 0.005337
a The operational taxonomic units (OTUs) were deﬁned with 97% similarity level.
b The coverage percentage (Good’s), richness estimators (ACE and Chao1) and diversity indices (Shannon and Simpson) were calculated using Good’s method and the
mothur program, respectively.
c The Shannon index of evenness was calculated with the formula E = H/ln(S), where H is the Shannon diversity index and S is the total number of sequences in that group.
* Compared with HCs, P < 0.05.
Table 2
Descriptive data of included adults in the study.
Parameter Value for groups
Healthy controls (n = 30) Active-MDD (n = 29) Responsed-MDD (n = 17)
Sociodemographics
Proportion of Females, No. (%)* 15 (50%) 11 (38%) 8 (47%)
Age (years; means ± SD) (range)– 26.8 (5.4) (18–38) 25.3 (5.4) (18–40) 27.1 (5.4) (19–40)
BMI (means ± SD) (range)– 19.6 (3.4) (18.6–23.5) 20.3 (3.4) (19.6–22.5) 21.8 (3.4) (21.6–23.6)
Employed, No. (%)* 26 (87%) 21 (72%) 14 (82%)
High school or less, No. (%)* 12 (43%) 9 (31%) 4 (24%)
Smoking, No. (%)* 2 (7%) 3 (10%) 2 (12%)
Antidepressant treatment
SSRIs or SNRIs treatment, No. (%) 0 21 (72%) 17 (100%)#
Atypical antipsychotic, No. (%) 0 7 (24%) 5 (29%)
Benzodiazepines, No. (%) 0 24 (83%) 10 (58.9%)
Blood markers
BDNF (ng/ml), mean (SD)– 12.77 (4.60) 6.38 (4.37) 9.00 (4.54)#
IL-6 (pg/ml), mean (SD)– 30.66 (2.99) 27.83 (8.56) 27.36 (6.03)
IL-1b (pg/ml), mean (SD)– 0.10 (0.16) 0.13 (0.36) 0.10 (0.07)
TNF-a (pg/ml), mean (SD)– 73.09 (322.34) 102.88 (515.05) 27.53 (37.64)
Severity of depressive symptoms
HAMDS§ NA 29.8 (7.6) 8.3 (4.6)#
MADRS§ NA 27.4 (8.5) 6.9 (4.3)#
* Chi-square test; – One-way ANOVA; § Student’s t test;  compared with HCs, P < 0.05; # compared with A-MDD, P < 0.05; Abbreviations:
MDD, major depressive disorder; SD, standard deviation; BMI, body mass index; SSRIs, selective serotonin reuptake inhibitors; SNRIs, selective
norepinephrine reuptake inhibitors; BDNF, brain-derived neurotrophic factor; IL-6, interleukin-6; IL-1b, interleukin-1 beta; TNF-a, tumor
necrosis alpha; HAMDS, Hamilton’s Depression Scale; MADRS, Montgomery–Asberg Depression Rating Scale; NA, not available.
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The raw pyrosequencing reads obtained from the sequencer
were denoised using Titanium PyroNoise software. According to
the barcode and primer sequences, the resulting pyrosequencing
reads were ﬁltered using a combination of tools from Mothur
(ver. 1.25.0; http://www.mothur.org) and custom Perl scripts.
Preliminary quality control steps were performed according to a
previous study. Using ChimeraSlayer, chimera sequences arising
from the PCR ampliﬁcation were detected and excluded from the
denoised sequences. The high-quality sequences were assigned to
samples according to the barcodes. The high-quality reads were
clustered into operational taxonomic units (OTUs) using Mothur.
OTUs that reached a 97% nucleotide similarity level were used
for alpha diversity (Shannon, Simpson, and evenness indices), rich-
ness (ACE and Chao1), Good’s coverage, Venn diagram, and rarefac-
tion curve analyses using Mothur according to our previous study
(Ling et al., 2014). Phylogenetic beta diversity measures, such as
unweighted UniFrac distance metrics analysis and principal coor-
dinate analysis, were performed using OTUs for each sample and
the Mothur program.
Taxonomy-based analyses were performed by classifying each
sequence using the Naïve Bayesian Classiﬁer program of the
Michigan State University Center for Microbial Ecology Ribosomal
Database Project database (http://rdp.cme.msu.edu/) with a 50%
bootstrap score. The metastats program from Mothur was used to
identify signiﬁcantly different phylotypes among the groups.
Microorganism features distinguishing fecal microbiota speciﬁc to
MDD were identiﬁed using the linear discriminant analysis (LDA)
effect size (LEfSe) method (http://huttenhower.sph.harvard.edu/
lefse/) for biomarker discovery, which emphasizes both statistical
signiﬁcance and biological relevance (metagenomic biomarker dis-
covery and explanation). LEfSe uses the Kruskal–Wallis rank-sum
test with a normalized relative abundancematrix to detect features
with signiﬁcantly different abundances between assigned taxa and
performs LDA to estimate the effect size of each feature. An alpha
signiﬁcance level of 0.05 and an effect-size threshold of 2 were used
for all biomarkers. Correlations between variables were calculated
using Spearman’s rank-correlation analysis. Statistical analyses
were performed using the SPSS ver. 16.0 data analysis software
(SPSS Inc., Chicago, IL, USA). All tests for signiﬁcance were two
sided, and a P < 0.05 was considered to indicate signiﬁcance.
2.6. Accession numbers
The sequence data from this study have been deposited in the
GenBank Sequence Read Archive with the accession number
SRP042956.
3. Results
3.1. Collection of 16S data
We obtained 608,575 high-quality sequences, accounting for
64.6% of the valid sequences (941,616 reads in total) from 76 par-
ticipant fecal samples. According to barcode and primer sequence
ﬁltering, an average of 8007 (range, 4983–12,776) sequences per
barcoded sample was recovered for downstream analysis. Thus,
229,038 sequences were obtained from control subjects for the
phylogenetic analysis, whereas 244,508 sequences were obtained
from the MDD group and 135,029 from the HC group. The total
number of unique sequences from the three groups was 18,022,
and all phylotypes were represented. In particular, 8271 species-
level OTUs in control subjects, 10,365 OTUs in the A-MDD group,
and 6737 OTUs in R-MDD group were obtained. Detailed character-
istics of each sample are shown in Table S1. Coverage approached97.0% for all sequences in the three groups, indicating good
sequencing depth for investigation of the depression-associated
fecal microbiota.
3.2. Overall structure of the fecal bacterial communities
We evaluated the ecological features of the fecal bacterial com-
munities in the A-MDD, R-MDD, and HC groups using a variety of
indices based on the OTU level (Table 1). Species richness is the
number of bacterial species assigned by OTUs detected in the sam-
ples. Richness estimates were obtained from the observed number
of species by extrapolation using estimators such as the ACE and
Chao1 indices. Evenness is the degree of homogeneity of abun-
dance of the species detected in the samples. Diversity estimates
were obtained from species richness and evenness was obtained
by using several different indices to conﬁrm our results. Bacterial
diversity was signiﬁcantly higher in the A-MDD group than that
in the controls, as indicated by the Shannon index (Table 1). No
other signiﬁcant differences were found among the three groups
(Suppl. Fig. S1). The trend in species richness in patients with
depression was similar to that of the HCs, based on the rarefaction
analysis estimates (Suppl. Fig. S2). The OTU analysis showed a long
tail in the rank abundance curves, indicating that the majority of
OTUs were present at low abundance (Suppl. Fig. S3). A beta diver-
sity analysis indicates the extent of similarity between microbial
communities by measuring the degree to which membership or
structure is shared between communities. Due to signiﬁcant
interindividual variation, the fecal microbiotas of the three groups
could not be divided into clusters according to community compo-
sition using unweighted UniFrac metrics and could not be sepa-
rated clearly by principal coordinates analysis (Suppl. Fig. S4).
However, the clustering was complemented by an analysis of bac-
terial richness using the number of shared and unique OTUs in the
three groups by a Venn diagram, which was generated to compare
OTUs among the three groups (Suppl. Fig. S5).
3.3. Altered microbiota composition in A-MDD
We usedMetastats to investigate the associations between fecal
microbiota composition and A-MDD. The A-MDD and HC groups
exhibited statistically signiﬁcant differences with regard to the
three dominant phyla, Firmicutes, Bacteroidetes, and
Proteobacteria; the A-MDD and HC groups also showed statisti-
cally signiﬁcant differences with regard to Fusobacteria and
Actinobacteria (Fig. 2a). We found 11 statistically signiﬁcant
differences between A-MDD and HC groups at the family
level. The relative proportions of Acidaminococcaceae,
Enterobacteriaceae, Fusobacteriaceae, Porphyromonadaceae, and
Rikenellaceae were signiﬁcantly higher in the A-MDD group com-
pared with the HC group; we also found signiﬁcantly lower levels
of Bacteroidaceae, Erysipelotrichaceae, Lachnospiraceae,
Prevotellaceae, Ruminococcaceae, and Veillonellaceae in the
A-MDD than in the HC group (Fig. 2b).
Bacterial communities were also compared at the genus level.
The abundances of 72 genera differed between the A-MDD and
HCs groups, including 15 predominant (>1% of the total sequences
in either group) and 57 less-predominant genera. Among the
different predominant genera, Alistipes, Blautia, Clostridium XIX,
Lachnospiracea incertae sedis, Megamonas, Parabacteroides,
Parasutterella, Phascolarctobacterium, Oscillibacter and Roseburia
were relatively more abundant in the A-MDD vs. HC group;
However, Bacteroides, Dialister, Faecalibacterium, Prevotella, and
Ruminococcus were relatively more abundant in the HC vs.
A-MDD group (Fig. 2c).
The metagenome analysis LEfSe approach was applied to
identify the key phylotypes responsible for the difference between
Fig. 2. Taxonomic differences of fecal microbiota between HC and A-MDD groups. Comparison of relative abundance at the bacterial phylum (a), family (b) and genus (c)
levels between HC and A-MDD groups. # indicates P < 0.05. LEfSe identiﬁed the most differentially abundant taxons between HC and A-MDD groups. Taxonomic cladogram
obtained from LEfSe analysis of 16S sequences (relative abundanceP0.5%). (Red) A-MDD taxa; (Green) taxa enriched in HCs. The brightness of each dot is proportional to its
effect size (d). HC-enriched taxa are indicated with a positive LDA score (green), and taxa enriched in A-MDD have a negative score (red). Only taxa meeting an LDA signiﬁcant
threshold >2 are shown (e). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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and Clostridium XlVb, which were most abundant in the A-MDD,
and Faecalibacterium, Dialister, Ruminococcus, Escherichia/Shigella,
Haemophilus, which were most abundant in the HCs, were the
dominant phylotypes that contributed to the difference between
the intestinal microbiota of A-MDD and HCs (Fig. 2d and e).
3.4. Altered microbiota composition in R-MDD
A taxonomy-based comparison was performed to determine the
differences between themicrobiota of R-MDDandHC groups. At the
phylum level, Firmicutes, Fusobacteria, and Actinobacteria were
signiﬁcantly more abundant in the fecal microbiota of the HC than
the R-MDD group, whereas Bacteroidetes and Proteobacteria were
signiﬁcantly more abundant in the fecal microbiota of the R-MDD
group (Fig. 3a). Compared with the HC group, the abundances of
the more prevalent families (Acidaminococcaceae, Bacteroidaceae,
Enterobacteriaceae, Porphyromonadaceae, and Rikenellaceae) were
increased in the R-MDD group, whereas those of the
Lachnospiraceae, Ruminococcaceae, and Veillonellaceae families
were decreased (Fig. 3b). Several signiﬁcant differences between
the HC and R-MDD groups were observed at the genus level.
Among the abundant genera, ﬁve (Alistipes, Bacteroides,
Parabacteroides, Phascolarctobacterium, and Roseburia) were
increased in the R-MDD group, whereas another six (Escherichia/
Shigella, Oscillibacter, Dialister, Faecalibacterium, Prevotella, and
Ruminococcus) were decreased signiﬁcantly in this group (Fig. 3c).The metagenome analysis LEfSe approach was also applied to
identify the key phylotypes responsible for the difference between
the R-MDD and HC groups. Clostridium sensu stricto, Ruminococcus,
and Haemophilus, which were abundant in the HCs, were the key
phylotypes that contributed to the difference in the intestinal
microbiota composition between R-MDD patients and the HCs
(Fig. 3d and e).
3.5. Associations among fecal microbiota and clinical indicators
We evaluated the inﬂammatory state and BDNF levels in the
serum of the A-MDD and R-MDD patients compared with that of
the HCs. The analysis was performed by measuring IL-6, TNF-a,
IL-1b, and BDNF levels in 29 A-MDD, 13 R-MDD, and 30 HC individ-
uals (Table 2). No signiﬁcant difference in serum inﬂammatory bio-
marker concentrations was observed in the A-MDD and R-MDD
groups compared with the HCs. However, the BDNF levels in the
A-MDD and R-MDD groups were lower than those in the HCs
(P < 0.01).
We also evaluated correlations among the relative abundances
of bacterial genera, the BDNF, serum inﬂammatory biomarkers,
and the severity of depressive symptoms. With signiﬁcantly
interindividual variability, we identify that only one genus,
Clostridium XIVb, negatively correlated with the sereum BDNF level
(P < 0.05) (Fig. 4a), while other key phylotypes showed no strong
correlation with serum BDNF level. In addition, there were negative
relationships between the relative abundance of Faecalibacterium
Fig. 3. Taxonomic differences of fecal microbiota between HC and R-MDD groups. Comparison of relative abundance at the bacterial phylum (a), family (b) and genus (c)
levels between HC and R-MDD groups. # indicates P < 0.05. Taxonomic cladogram obtained from LEfSe analysis of 16S sequences (relative abundanceP0.5%). (Red) R-MDD
taxa; (Green) taxa enriched in HCs (d). HC-enriched taxa are indicated with a positive LDA score (green), and taxa enriched in R-MDD have a negative score (red) (e). (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 4. (a) Correlation between serum BDNF level and the relative abundance of the genera Clostridium XIVb. (b) and (c) Correlation between the relative abundance of the
genera Faecalibacterium and severity of depressive symptoms. The spearman rank correlation (R) and probability (P) were used to evaluate statistical importance. ⁄One outlier
was excluded for better representation of the data.
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remove the one outlier from correlation analysis, the results were
the same.4. Discussion
This study found differences in alpha diversity, and in the levels
of speciﬁc bacterial taxa in gut microbiomes associated with MDD,
particularly among patients with clinically signiﬁcant depressive
symptoms. To date, only one study by Naseribafrouei et al.
(2014) had compared the fecal microbiota of depressed (n = 37)
and non-depressed (n = 18) individuals, with no signiﬁcant group
differences reported in microbiota diversity. In the present study,
fecal microbial diversity (estimated using the Shannon Index)
was unexpectedly somewhat greater in A-MMD patients.Although greater bacterial diversity is potentially beneﬁcial to
human health, its role in CNS function remains subject to debate.
A previous study demonstrated greater gut microbe diversity in
formula- vs. breast-fed infants (Fan et al., 2014; Roger et al.,
2010). However, breast-fed infants were characterized by superior
neurodevelopmental outcomes and higher intelligence test scores
(Kramer et al., 2008). Furthermore, increased gut microbe diversity
and richness was also detected in a sample of autistic children
(Finegold et al., 2010); therefore, the precise consequences of
increased bacterial diversity for A-MDD remains unclear. It should
be noted that the diversity of gut bacteria is inﬂuenced by several
factors, including health status, age, diet, and antibiotic treatment
(Lozupone et al., 2012). In contrast with our study, –Naseribafrouei
et al. (2014) recruited a control group from an outpatient neurolog-
ical unit. Although no disorders were evident in these patients,
their bacterial diversities may have differed from ours because
192 H. Jiang et al. / Brain, Behavior, and Immunity 48 (2015) 186–194we used healthy subjects as a control group. Furthermore, as bac-
terial diversity changes with age, the inconsistent results may be
explained by differences in age between the samples of the two
studies. In addition, dietary differences between Western and
Eastern countries may have also contributed to differences in bac-
terial diversity. However, both studies lack data on the dietary
habits of subjects; this is a limitation of both extant studies inves-
tigating the association between gut microbiota and depression.
However, no signiﬁcant difference was found in between the body
mass indices of the study groups, which argues against the exis-
tence of major dietary differences.
In our study, intestinal dysbiosis was characterized by signiﬁ-
cant taxonomical differences between three of the major phyla in
A-MDD vs. control subjects. Bacteroidetes and Proteobacteria were
signiﬁcantly more abundant in A-MDD subjects, whereas the pro-
portion of Firmicutes was markedly lower. Parabacteroides and
Alistipes, of the Porphyromonadaceae and Rikenellaceae families,
respectively, principally contributed to the increase in
Bacteroidetes. Bailey et al. (2011) also reported greater genus
Parabacteroides abundance in mice exposed to social stressors vs.
non-stressed controls. Naseribafrouei et al. (2014) reported enrich-
ment of the Alistipes in the depressed subjects. Alistipes species are
indole-positive and may thus inﬂuence tryptophan availability
(Song et al., 2006). As tryptophan is also the precursor of serotonin,
increased abundance of Alistipes might therefore disrupt the bal-
ance in the intestinal serotonergic system. Saulnier et al. (2011)
found that higher levels of Alistipes were associated with a greater
frequency of abdominal pain in patients with irritable bowel syn-
drome, and speculated that Alistipes is associated with gut inﬂam-
mation; thus, further research is needed to clarify the role of this
genus in gut inﬂammation and the serotonergic system in depres-
sion. A decrease in Bacteroides is assumed to be associated with
metabolic diseases such as obesity and diabetes (Bervoets et al.,
2013; Zhang et al., 2013); depression and metabolic disease
comorbidity is also common (Butnoriene et al., 2014). Consistent
with previous animal and human studies (Bailey et al., 2011;
Naseribafrouei et al., 2014), Bacteroides expression was signiﬁ-
cantly decreased in A-MDD vs. control patients. Although obesity
and diabetes were exclusionary criteria, an association between
Bacteroides and metabolism cannot be ruled out in our depressed
patients.
Expression of the Lachnospiraceae and Ruminococcaceae fami-
lies, within the phylum Firmicutes, was decreased in the A-MDD
vs. the control group. Bangsgaard Bendtsen et al. (2012) also
reported that the expression of various species of
Lachnospiraceae and Ruminococcaceae in mice correlated with
behavioral changes induced by stress. The Lachnospiraceae family,
which includes the Roseburia, Blautia, and Lachnospiraceae incertae
sedis genera, is known to participate in the breakdown of carbohy-
drates into short-chain fatty acids (SCFAs) (Duncan et al., 2007); a
decrease in these fermentation-related bacteria precipitates a
decline in SCFA production, which in turn causes intestinal barrier
dysfunction (Vince et al., 1990; Wong et al., 2006). The genus
Faecalibacterium, afﬁliated with the Ruminococcaceae family, was
highly enriched in healthy controls. An extensive body of data
demonstrates that depression is associated with a chronic low-
grade inﬂammatory response (Berk et al., 2013). Faecalibacterium
was characterized by anti-inﬂammatory activity within the gut
(Sokol et al., 2008); we speculated that the relative abundance of
this genus in depressed subjects at least partly mediated the
degree of inﬂammation. However, Phascolarctobacterium
(Acidaminococcaceae family) and Clostridium XIX (Clostridiaceae
family) were signiﬁcantly increased in patients with A-MDD.
Acidaminococcaceae enrichment in the A-MDD group also
accorded with previous research using pyrosequencing fecal sam-
ples, in which patients with both irritable bowel syndrome anddepression exhibited signiﬁcant fecal overgrowth of
Acidaminococcaceae (Jeffery et al., 2012). In another study, in
which depression in rats was induced by stress, Clostridiaceae
was prevalent in the cecum (Bailey et al., 2011). Oscillibacter, of
the family Oscillospiraceae, was also signiﬁcantly increased in A-
MDD patients. Naseribafrouei et al. (2014) similarly reported
greater Oscillibacter enrichment in depressed vs. non-depressed
subjects.
We also detected overgrowth of the phylum Proteobacteria,
speciﬁcally of the Gammaproteobacteria class (including
Enterobacteriales and Enterobacteriaceae) in our A-MDD group.
The Enterobacteriaceae family includes inﬂammogenic enteric
pathogens such as Hafnia alvei, Pseudomonas aeruginosa,
Morganella morganii, Proteus mirabilis, Pseudomonas putida,
Citrobacter koseri and Klebsielle pneumonia (Maes et al., 2008;
Maes et al., 2012, 2013). All of these gram-negative bacteria are
observed in normal gut ﬂora. Increased permeability of the gut
wall in depressed patients may allow invasive gram negative bac-
teria to translocate into mesenteric lymph nodes or the systemic
circulation (Berg and Garlington, 1979; O’Malley et al., 2010).
Clinical depression is accompanied by increased plasma
immunoglobulin (Ig)A and/or IgM, which are directed against these
bacteria (Maes et al., 2012). Moreover, previous studies have
demonstrated that the presence of these pathogenic bacteria in
the gastrointestinal tract can induce behavioral and psychological
changes in animals and humans (Goehler et al., 2008; Lowe et al.,
2014; Lyte et al., 1998, 2006).
We also observed that the levels of several genera in the R-MDD
group were differed from those in the HC group. It should be noted
that atypical antipsychotic use was widespread among our
patients. A previous animal study demonstrated that chronic
antipsychotic administration increased and decreased the relative
abundance of Firmicutes and Bacteroidetes, respectively, in the
caecum (Davey et al., 2012, 2013). Although our study had very
strict inclusion criteria to control potential confounders, we cannot
completely rule out the possibility that atypical antipsychotics
may have affected our results. Therefore, it remains unclear
whether these changes were caused by atypical antipsychotics or
depressive symptoms. This is a major limitation of this study,
and further research involving patients who are not receiving
antipsychotics is needed to elucidate this issue.
Depression is associated with biomarkers of inﬂammation, such
as elevated IL-6, TNF-a, and IL-1b levels (Lopresti et al., 2014).
Alterations in the gut microbiota of patients with depression may
modulate the inﬂammatory response. It was unexpected that no
difference in serum inﬂammatory agents was detected among the
three groups, probably due to the high prevalence of antidepressant
use among the included patients (Hiles et al., 2012). But we found
the serum level of BDNF differed signiﬁcantly among these three
groups. Previous studies have reported that changes in hippocam-
pal BDNFmRNA and protein levels are related to the gut microbiota
composition (Bercik et al., 2010, 2011; Neufeld et al., 2011). Our
present results demonstrate that the prevalence of Clostridium
XIVb was negatively associated with the serum BDNF level. We
used the HAMD and MARDS scales to evaluate depressive symp-
toms in patients with MDD. Although a negative correlation was
found between the abundance of Faecalibacterium and disease
severity, we did not use HAMDS andMADRS tomeasure the depres-
sive symptoms of the HCs. Hence, these ﬁndings need to be treated
cautiously due to the risk of overestimation in small cohorts.
Furthermore, the absence of HCs’ scores may also explain the lim-
ited statistically signiﬁcant correlations between gut microbiota
and depressive severity.
In summary, this study contributes to previous reports on the
involvement of gut microbiota in psychiatric disorders by demon-
strating that microbial populations are associated with depression.
H. Jiang et al. / Brain, Behavior, and Immunity 48 (2015) 186–194 193Investigations of whether the Faecalibacterium protects against
depression or whether Enterobacteriaceae and Alistipes are indica-
tors of increased permeability of the gut wall are needed. Future
studies involving larger cohorts and incorporating metagenomics,
or even metabolomics, may elucidate the temporal and causal rela-
tionships between gut microbiota and depression.
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